SBN 0.00% 0.0¢ sun biomedical limited

despatch of rights issue, page-14

  1. 3,715 Posts.
    The big thing Vin will be the benchmark set through successful testing.

    OraLine will be shown to be:

  2. Easy to use
  3. Non invasive
  4. Accurate
  5. Relatively inexpensive

    There will no doubt be a government funded study (possibly a PhD thesis) on its inception and reception among schools and its effects.

    Positive use through that sort of environment will set Sun up for years.

    Cheers



 
watchlist Created with Sketch. Add SBN (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.